EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection

Marco Ratta iD, Donia Skanji, Zhaoyang Teng iD, Gaëlle Saint-Hilary iD, Mauro Gasparini iD, Pavel Mozgunov iD

Statistics in Medicine · 2026-11 · 45 (25-27)

DOI: 10.1002/sim.70790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, online erschienen am 16.11.2026. Verfasst von Marco Ratta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Matematiche, Politecnico di Torino, Torino, Italy. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Research Design. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seamless Phase II/III designs are increasingly employed to accelerate drug development, particularly in settings where multiple doses of the same compound need to be evaluated in parallel. In such designs, a restricted subset of doses is selected at the first stage of the trial and subsequently carried forward to the second stage, where efficacy is assessed against control. Dose selection is typically based on a single efficacy endpoint, ensuring consistency between interim decision‐making and final hypothesis testing. However, safety is typically not formally integrated into the selection process during the design stage, which can be problematic, as it may lead to advancing doses that are effective but potentially harmful. In this work, we propose a novel multi‐arm two‐stage design in which the dose with the most favorable benefit‐risk profile at the interim analysis is selected and continued into Phase III. Benefit‐risk assessment is conducted using probabilistic multi‐criteria decision analysis (MCDA), where information from multiple efficacy and safety endpoints is combined into a single aggregated score. For the proposed design, we derive an analytical expression for the decision boundary, ensuring strong control of the Type I error rate, and provide guidance on sample size determination. The operating characteristics are evaluated through extensive simulation studies and compared with existing designs from the literature, demonstrating that the proposed approach is particularly effective in terminating potentially harmful doses at an early stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicResearch DesignHumansRisk AssessmentDose-Response Relationship, DrugDecision Support TechniquesEndpoint DeterminationComputer SimulationModels, Statistical

Stichwörter der Autor:innen

multiplicitymulti‐criteria decision analysisquantitative benefit‐risk assessmentseamless designs

Autor:innen und Institutionen

  • Dipartimento di Scienze Matematiche, Politecnico di Torino, Torino, Italy.
  • Department of Statistical Methodology, Saryga, Tournus, France.
  • Servier National Research Institute (IRIS), Servier, Gif-sur-Yvette, France.
  • Astellas Pharma, Boston, Massachussets, USA.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

ORCID-Profile: Marco Ratta, Zhaoyang Teng, Gaëlle Saint-Hilary, Mauro Gasparini, Pavel Mozgunov

Förderung

  • Medical Research Council
  • National Institute for Health and Care Research

Zitieren

APA

Ratta, M., Skanji, D., Teng, Z., Saint-Hilary, G., Gasparini, M., & Mozgunov, P. (2026). Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection. Statistics in Medicine, 45(25-27). https://doi.org/10.1002/sim.70790

Vancouver

Ratta M, Skanji D, Teng Z, Saint-Hilary G, Gasparini M, Mozgunov P. Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection. Statistics in Medicine. 2026;45(25-27). doi:10.1002/sim.70790

BibTeX
@article{Ratta2026,
  author = {Ratta, Marco and Skanji, Donia and Teng, Zhaoyang and Saint-Hilary, Gaëlle and Gasparini, Mauro and Mozgunov, Pavel},
  title = {Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {25-27},
  doi = {10.1002/sim.70790}
}
Kostenlos starten →